Jensen IS, Wu E, Cyr PL , Claussen M, Winkler T, Salhuddin K, Prats J, et al. Cost-consequence analysis of using cangrelor in high angiographic risk percutaneous coronary intervention (PCI) patients: A US hospital perspective. Transcatheter Cardiovascular Therapeutics (TCT), San Diego, CA, 2018.
Publication: Abstracts and Presentations
Hathway J, Purdum AG, Lin VW, Cyr PL , Westin J, Jensen IS. A budget impact model of Axicabtagene Ciloleucil in a US population of patients with relapsed/refractory large B-cell lymphoma (RR-LBCL). European Blood and Marrow Transplantation Meeting, Lisbon Portugal, 2018.
Publication: Abstracts and Presentations
Hathway J, Purdum AG, Lin VW, Cyr PL , Westin J, Jensen IS. A budget impact model of axicabtagene ciloleucel (Axi-cel) in an US population of patients with relapsed or refractory large b-cell lymphoma (RR-LBCL). Podium presentation at ISPOR 23th Annual International Meeting, Baltimore MD, 2018.
Publication: Abstracts and Presentations
Sacks NC , Cyr PL , Louie AC, Liu Ym Chiarella MT, Sharma A, Chung KC. 2018. Burden of acute myeloid leukemia among older, newly diagnosed patients: Retrospective analysis of data from the 2010-2012 Medicare limited data set. Clin Ther 40(5):692–703.e2; doi: 10.1016/j.clinthera.2018.03.012 .
View Abstract
Publication: Manuscripts
2017
Wu E, Jensen IS, Cyr PL , Kisner H. Economic model shows that guideline recommended testing of patients with early symptoms of myeloma results in improved patient outcomes and decreased hospital costs. American Society of Hematology, Atlanta GA, 2017.
A Division of